Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: A pragmatic pre-post study

Neli S. Slavova-Azmanova, Catalina Lizama, Claire E. Johnson, Herbert P. Ludewick, Leanne Lester, S. Karunarathne, M. Phillips

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    © 2016 Slavova-Azmanova et al. Background: Utilisation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and guide sheath (EBUS-GS) for diagnosis and staging of lung cancer is gaining popularity, however, its impact on clinical practice is unclear. This study aimed to determine the impact of the introduction of endobronchial ultrasound-guided procedures (EBUS) on time to management decision for lung cancer patients, and on the utilisation of other invasive diagnostic modalities, including CT-guided trans-thoracic needle aspiration (CT-TTNA), bronchoscopy, and mediastinoscopy. Methods: Hospital records of new primary lung cancer patients presenting in 2007 and 2008 (Pre-EBUS cohort) and in 2010 and 2011 (Post-EBUS cohort) were reviewed retrospectively. Results: The Pre-EBUS cohort included 234 patients. Of the 326 patients in the Post-EBUS cohort, 90 had an EBUS procedure (EBUS-TBNA for 19.0 % and EBUS-GS for 10.4 % of cases). The number of CT-TTNAs and bronchoscopies decreased following the introduction of EBUS (p = 0.015 and p
    Original languageEnglish
    Article number44
    JournalBMC Cancer
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - 2016

    Fingerprint

    Time Management
    Lung Neoplasms
    Needles
    Bronchoscopy
    Mediastinoscopy
    Hospital Records

    Cite this

    @article{c4d67ed2e82944d1b1433408f7175217,
    title = "Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: A pragmatic pre-post study",
    abstract = "{\circledC} 2016 Slavova-Azmanova et al. Background: Utilisation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and guide sheath (EBUS-GS) for diagnosis and staging of lung cancer is gaining popularity, however, its impact on clinical practice is unclear. This study aimed to determine the impact of the introduction of endobronchial ultrasound-guided procedures (EBUS) on time to management decision for lung cancer patients, and on the utilisation of other invasive diagnostic modalities, including CT-guided trans-thoracic needle aspiration (CT-TTNA), bronchoscopy, and mediastinoscopy. Methods: Hospital records of new primary lung cancer patients presenting in 2007 and 2008 (Pre-EBUS cohort) and in 2010 and 2011 (Post-EBUS cohort) were reviewed retrospectively. Results: The Pre-EBUS cohort included 234 patients. Of the 326 patients in the Post-EBUS cohort, 90 had an EBUS procedure (EBUS-TBNA for 19.0 {\%} and EBUS-GS for 10.4 {\%} of cases). The number of CT-TTNAs and bronchoscopies decreased following the introduction of EBUS (p = 0.015 and p",
    author = "Slavova-Azmanova, {Neli S.} and Catalina Lizama and Johnson, {Claire E.} and Ludewick, {Herbert P.} and Leanne Lester and S. Karunarathne and M. Phillips",
    year = "2016",
    doi = "10.1186/s12885-016-2081-z",
    language = "English",
    volume = "16",
    journal = "BMC Cancer",
    issn = "1471-2407",
    publisher = "BioMed Central",
    number = "1",

    }

    TY - JOUR

    T1 - Impact of the introduction of EBUS on time to management decision, complications, and invasive modalities used to diagnose and stage lung cancer: A pragmatic pre-post study

    AU - Slavova-Azmanova, Neli S.

    AU - Lizama, Catalina

    AU - Johnson, Claire E.

    AU - Ludewick, Herbert P.

    AU - Lester, Leanne

    AU - Karunarathne, S.

    AU - Phillips, M.

    PY - 2016

    Y1 - 2016

    N2 - © 2016 Slavova-Azmanova et al. Background: Utilisation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and guide sheath (EBUS-GS) for diagnosis and staging of lung cancer is gaining popularity, however, its impact on clinical practice is unclear. This study aimed to determine the impact of the introduction of endobronchial ultrasound-guided procedures (EBUS) on time to management decision for lung cancer patients, and on the utilisation of other invasive diagnostic modalities, including CT-guided trans-thoracic needle aspiration (CT-TTNA), bronchoscopy, and mediastinoscopy. Methods: Hospital records of new primary lung cancer patients presenting in 2007 and 2008 (Pre-EBUS cohort) and in 2010 and 2011 (Post-EBUS cohort) were reviewed retrospectively. Results: The Pre-EBUS cohort included 234 patients. Of the 326 patients in the Post-EBUS cohort, 90 had an EBUS procedure (EBUS-TBNA for 19.0 % and EBUS-GS for 10.4 % of cases). The number of CT-TTNAs and bronchoscopies decreased following the introduction of EBUS (p = 0.015 and p

    AB - © 2016 Slavova-Azmanova et al. Background: Utilisation of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and guide sheath (EBUS-GS) for diagnosis and staging of lung cancer is gaining popularity, however, its impact on clinical practice is unclear. This study aimed to determine the impact of the introduction of endobronchial ultrasound-guided procedures (EBUS) on time to management decision for lung cancer patients, and on the utilisation of other invasive diagnostic modalities, including CT-guided trans-thoracic needle aspiration (CT-TTNA), bronchoscopy, and mediastinoscopy. Methods: Hospital records of new primary lung cancer patients presenting in 2007 and 2008 (Pre-EBUS cohort) and in 2010 and 2011 (Post-EBUS cohort) were reviewed retrospectively. Results: The Pre-EBUS cohort included 234 patients. Of the 326 patients in the Post-EBUS cohort, 90 had an EBUS procedure (EBUS-TBNA for 19.0 % and EBUS-GS for 10.4 % of cases). The number of CT-TTNAs and bronchoscopies decreased following the introduction of EBUS (p = 0.015 and p

    U2 - 10.1186/s12885-016-2081-z

    DO - 10.1186/s12885-016-2081-z

    M3 - Article

    VL - 16

    JO - BMC Cancer

    JF - BMC Cancer

    SN - 1471-2407

    IS - 1

    M1 - 44

    ER -